References
Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 645–63
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321–5
Chan L, Mulgaonkar S, Walker R, et al. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006; 81: 1290–7
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boswell, A., Shehata, M. Conversion from Mycophenolate Mofetil to Enteric-coated Mycophenolate Sodium (myfortic®) in Patients with Gastrointestinal Side Effects: Case Studies. Drugs 66 (Suppl 2), 19–22 (2006). https://doi.org/10.2165/00003495-200666002-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200666002-00006